相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2019)
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K-pneumoniae
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2019)
Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniaein mouse thigh and lung infection models
Cornelia B. Landersdorfer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients
Alessandro Russo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents
Sameer S. Kadri et al.
CLINICAL INFECTIOUS DISEASES (2018)
Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net
Marlieke E. A. de Kraker et al.
CLINICAL INFECTIOUS DISEASES (2018)
Management of KPC-producing Klebsiella pneumoniae infections
M. Bassetti et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp.
E. Matuschek et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
New antibiotics for ventilator-associated pneumonia
Matteo Bassetti et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2018)
Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria
Lindsay M. Avery et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Cefiderocol: a novel siderophore cephalosporin
Justin J. Choi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Ceftolozane/tazobactam: place in therapy
Daniele Roberto Giacobbe et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection
Maddalena Giannella et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment
Paolo Gaibani et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul et al.
LANCET INFECTIOUS DISEASES (2018)
Colistin versus colistin plus meropenem for severe infections
Daniele Roberto Giacobbe
LANCET INFECTIOUS DISEASES (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in US Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility
Dee Shortridge et al.
MICROBIAL DRUG RESISTANCE (2018)
Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment
Daniele Roberto Giacobbe et al.
SCIENTIFIC REPORTS (2018)
Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B
Josiane F. John et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model
Mojgan Sabet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations
George G. Zhanel et al.
DRUGS (2018)
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Salvage Therapy with CeftolozaneTazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
Juan Jose Caston et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella pneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study
D. R. Giacobbe et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
Valerio Del Bono et al.
VIRULENCE (2017)
Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies
D. R. Giacobbe et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
Combination therapy for extensively-drug resistant gram-negative bacteria
Ilias Karaiskos et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2017)
Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art
Alberto Enrico Maraolo et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2017)
Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy
Daniele Roberto Giacobbe et al.
INFECTION (2017)
Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis
Philipp P. Kohler et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2017)
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
Federico Pea et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
Matthew E. Falagas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods
Frieder Schaumburg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases
Helio S. Soder et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
Belen Gutierrez-Gutierrez et al.
LANCET INFECTIOUS DISEASES (2017)
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study
Hajo Grundmann et al.
LANCET INFECTIOUS DISEASES (2017)
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial A Randomized Clinical Trial
Joseph Solomkin et al.
JAMA SURGERY (2017)
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
Dongxu Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
What is antimicrobial stewardship?
O. J. Dyar et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from US Medical Centers, 2013 to 2016
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
H. Wright et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
Global antimicrobial resistance in Gram-negative pathogens and clinical need
Ursula Theuretzbacher
CURRENT OPINION IN MICROBIOLOGY (2017)
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds
Mordechai Grupper et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
Shuhei Matsumoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae
Ghady Haidar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from US Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015
Dee Shortridge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa
Jose M. Munita et al.
CLINICAL INFECTIOUS DISEASES (2017)
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015-Results from the SMART global surveillance program
Sibylle H. Lob et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2017)
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011
Michael A. Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa
Luisa Sorli et al.
BMC INFECTIOUS DISEASES (2017)
In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
Deanna J. Buehrle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms
Sherwin K. B. Sy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase
Wenjuan Wei et al.
JOURNAL OF CHEMOTHERAPY (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
Risk factors for infections due to carbapenem-resistant Klebsiella pneumoniae after open heart surgery
Antonio Salsano et al.
INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY (2016)
Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?
Cristina Garcia-Salguero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections
Maria Helena Rigatto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
M. Berrazeg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vivo Activities of Simulated Human Doses of Cefepime and Cefepime-AAI101 against Multidrug-Resistant Gram-Negative Enterobacteriaceae
Jared L. Crandon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Optimal Usage of Colistin: Are We Any Closer?
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2015)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study
D. R. Giacobbe et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections
Matteo Bassetti et al.
CURRENT OPINION IN CRITICAL CARE (2015)
Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance
Neang S. Ly et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study
Mario Tumbarello et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Catechol Siderophore Transport by Vibrio cholerae
Elizabeth E. Wyckoff et al.
JOURNAL OF BACTERIOLOGY (2015)
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Scott J. Hecker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae
Jared L. Crandon et al.
PATHOGENS (2015)
Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from US Hospitals
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
Rujipas Sirijatuphat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
Gabriel Cabot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram- Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012
A. Walkty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems
George L. Daikos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Early carbapenem-resistant Klebsiella pneumoniae bacteraemia: should we expand the screening?
D. R. Giacobbe et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
Eravacycline for the treatment of intra-abdominal infections
Matteo Bassetti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches
Ilias Karaiskos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Combination therapy for carbapenem-resistant Gram-negative bacteria
Mical Paul et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Activity of Ceftaroline-Avibactam Tested Against Contemporary Enterobacteriaceae Isolates Carrying β-Lactamases Prevalent in the United States
Mariana Castanheira et al.
MICROBIAL DRUG RESISTANCE (2014)
Siderophore-drug complexes: potential medicinal applications of the 'Trojan horse' strategy
Agnieszka Gorska et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Action Plan to combat infections due to carbapenem-resistant, Gram-negative pathogens in acute-care hospitals in Greece
Helena C. Maltezou et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2014)
Proliferation and significance of clinically relevant β-lactamases
Karen Bush
ANTIMICROBIAL THERAPEUTICS REVIEWS: THE BACTERIAL CELL WALL AS AN ANTIMICROBIAL TARGET (2013)
Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
Emanuele Durante-Mangoni et al.
CLINICAL INFECTIOUS DISEASES (2013)
Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens
Ana M. Sandri et al.
CLINICAL INFECTIOUS DISEASES (2013)
Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art
Remy A. Bonnin et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2013)
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
L. Silvia Munoz-Price et al.
LANCET INFECTIOUS DISEASES (2013)
Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome mec Types
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
George G. Zhanel et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2012)
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
S. M. Garonzik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates
D. M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City
David Landman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients
Matthew E. Falagas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa
Guilherme Henrique Campos Furtado et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections
M. E. Falagas et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Versatility of Aminoglycosides and prospects for their future
SB Vakulenko et al.
CLINICAL MICROBIOLOGY REVIEWS (2003)
In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa
EJ Giamarellos-Bourboulis et al.
JOURNAL OF CHEMOTHERAPY (2003)
分享论文
